Literature DB >> 23055475

Treatment of neurodevelopmental disorders in adulthood.

Eero Castrén1, Ype Elgersma, Lamberto Maffei, Randi Hagerman.   

Abstract

Brain development in neurodevelopmental disorders has been considered to comprise a sequence of critical periods, and abnormalities occurring during early development have been considered irreversible in adulthood. However, findings in mouse models of neurodevelopmental disorders, including fragile X, Rett syndrome, Down syndrome, and neurofibromatosis type I suggest that it is possible to reverse certain molecular, electrophysiological, and behavioral deficits associated with these disorders in adults by genetic or pharmacological manipulations. Furthermore, recent studies have suggested that critical period-like plasticity can be reactivated in the adult brain by environmental manipulations or by pharmacotherapy. These studies open up a tantalizing possibility that targeted pharmacological treatments in combination with regimes of training or rehabilitation might alleviate or reverse the symptoms of neurodevelopmental disorders even after the end of critical developmental periods. Even though translation from animal experimentation to clinical practice is challenging, these results suggest a rational basis for treatment of neurodevelopmental disorders in adulthood.

Entities:  

Mesh:

Year:  2012        PMID: 23055475      PMCID: PMC3500763          DOI: 10.1523/JNEUROSCI.3287-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  78 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Structural and functional recovery from early monocular deprivation in adult rats.

Authors:  Tommaso Pizzorusso; Paolo Medini; Silvia Landi; Sara Baldini; Nicoletta Berardi; Lamberto Maffei
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-18       Impact factor: 11.205

3.  Neurofibromin regulates corticostriatal inhibitory networks during working memory performance.

Authors:  Carrie Shilyansky; Katherine H Karlsgodt; Damian M Cummings; Kyriaki Sidiropoulou; Molly Hardt; Alex S James; Dan Ehninger; Carrie E Bearden; Panayiota Poirazi; J David Jentsch; Tyrone D Cannon; Michael S Levine; Alcino J Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

5.  Long-term plasticity of visually evoked potentials in humans is altered in major depression.

Authors:  Claus Normann; Daniela Schmitz; Andrea Fürmaier; Carsten Döing; Michael Bach
Journal:  Biol Psychiatry       Date:  2007-01-19       Impact factor: 13.382

6.  Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity.

Authors:  Elena Putignano; Giuseppina Lonetti; Laura Cancedda; Gianmichele Ratto; Mario Costa; Lamberto Maffei; Tommaso Pizzorusso
Journal:  Neuron       Date:  2007-03-01       Impact factor: 17.173

7.  A sensitive period for environmental regulation of eating behavior and leptin sensitivity.

Authors:  Marco Mainardi; Gaia Scabia; Teresa Vottari; Ferruccio Santini; Aldo Pinchera; Lamberto Maffei; Tommaso Pizzorusso; Margherita Maffei
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

8.  Impact of neurofibromatosis type 1 on school performance.

Authors:  Lianne C Krab; Femke K Aarsen; Arja de Goede-Bolder; Coriene E Catsman-Berrevoets; Willem F Arts; Henriette A Moll; Ype Elgersma
Journal:  J Child Neurol       Date:  2008-09       Impact factor: 1.987

9.  GABAergic inhibition in visual cortical plasticity.

Authors:  Alessandro Sale; Nicoletta Berardi; Maria Spolidoro; Laura Baroncelli; Lamberto Maffei
Journal:  Front Cell Neurosci       Date:  2010-03-31       Impact factor: 5.505

10.  Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Authors:  Aubin Michalon; Michael Sidorov; Theresa M Ballard; Laurence Ozmen; Will Spooren; Joseph G Wettstein; Georg Jaeschke; Mark F Bear; Lothar Lindemann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

View more
  26 in total

Review 1.  Developmental specification of metabolic circuitry.

Authors:  Amanda E Elson; Richard B Simerly
Journal:  Front Neuroendocrinol       Date:  2015-09-25       Impact factor: 8.606

2.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

Review 3.  The developmental stages of synaptic plasticity.

Authors:  Christian Lohmann; Helmut W Kessels
Journal:  J Physiol       Date:  2013-10-21       Impact factor: 5.182

4.  Investigation of genes important in neurodevelopment disorders in adult human brain.

Authors:  Gilles Maussion; Alpha B Diallo; Carolina O Gigek; Elizabeth S Chen; Liam Crapper; Jean-Francois Théroux; Gary G Chen; Cristina Vasuta; Carl Ernst
Journal:  Hum Genet       Date:  2015-07-21       Impact factor: 4.132

5.  TorsinA restoration in a mouse model identifies a critical therapeutic window for DYT1 dystonia.

Authors:  Jay Li; Daniel S Levin; Audrey J Kim; Samuel S Pappas; William T Dauer
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 6.  Progress toward treatments for synaptic defects in autism.

Authors:  Richard Delorme; Elodie Ey; Roberto Toro; Marion Leboyer; Christopher Gillberg; Thomas Bourgeron
Journal:  Nat Med       Date:  2013-06-06       Impact factor: 53.440

7.  Neuronal plasticity and antidepressant actions.

Authors:  Eero Castrén; René Hen
Journal:  Trends Neurosci       Date:  2013-02-01       Impact factor: 13.837

8.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

Review 9.  Highly specific structural plasticity of inhibitory circuits in the adult neocortex.

Authors:  Jerry L Chen; Elly Nedivi
Journal:  Neuroscientist       Date:  2013-03-08       Impact factor: 7.519

10.  Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior.

Authors:  Matthieu Genestine; Lulu Lin; Madel Durens; Yan Yan; Yiqin Jiang; Smrithi Prem; Kunal Bailoor; Brian Kelly; Patricia K Sonsalla; Paul G Matteson; Jill Silverman; Jacqueline N Crawley; James H Millonig; Emanuel DiCicco-Bloom
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.